$7.71

0.63 (8.90%)

7/23/2008 4:00 PM

Array BioPharma, Inc. (ARRY)

CAPS Rating:

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating ARRY

Add Stock to Watchlist

What the Community Thinks

Total Members

151 Outperforms

16 Underperforms

All-Stars

46 Outperforms

13 Underperforms

Wall Street

12 Outperforms

0 Underperforms

Members bullish on ARRY are also bullish on:

Members bearish on ARRY are also bearish on:

Ticker Tags

Biotechnology (294), Research (14), Micro Cap (4824), Medical Laboratories & Research (22), Rule Breakers Universe (161)
Suggest a tag

Array BioPharma, Inc. At A Glance

Current Price:	$7.71
Last Trade Time:	7/23/2008 4:00 PM
Open:	$7.06
Previous Close:	$7.08
Daily Range:	$6.90 - $7.72
52-Week Range:	$4.51 - $13.02
Volume:	482,849
Market Cap:	$336.58M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

ARRY VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for ARRY

Array BioPharma rises after gaining drug candidate funding
5/6/2008 5:48:00 PM - AP
Movers roundup: Lehman Brothers, Vulcan Materials
5/6/2008 4:48:00 PM - AP
Correction: Array BioPharma funding story
5/6/2008 10:13:00 AM - AP
Array BioPharma fiscal 3Q loss widens on higher costs
5/5/2008 6:34:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

7 Array BioPharma, Inc. (ARRY)

Avatar ForceMajeure26 (76.23) Submitted: 3/03/08 2:16 PM

What we have in Array BioPharma is what we see in Exelixis - only a year two earlier. And if there is a "safer" way for most of us to play the biotech sector it is to get in very early with small amounts and add over time in small pieces.
The reason to get in early is fairly straightforward - Array ...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 13 : 1 2 3 Next »

Recs 0 (ARRY) bsmith47 (71.90) Submitted: 4/17/08 11:41 AM : Start Price: $6.74 ARRY Score: 19.97 biotech darling will be bought out eventually by a big pharma for growth. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 7 (ARRY) ForceMajeure26 (76.23) Submitted: 3/03/08 2:16 PM : Start Price: $6.44 ARRY Score: 23.26 What we have in Array BioPharma is what we see in Exelixis - only a year two earlier. And if there is a "safer" way for most of us to play the biotech sector it is to get in very early with small amounts and add over time in small pieces. The reason to get in early is fairly straightforward - Array has 10 drugs in development - the majority in Cancer and 3 that will treat Inflammation (I.E. anything -itis). Much like its older brother Exelixis, Array has partnered with the big boys - your Genentechs, Amgens, Celgene, Eli Lilly, etc. With so many established players in the Biotech field willing to partner with Array, its stands to reason the company is producing some excellent compounds. As Charly Travers and Brian Lawler have taught me, most of these compounds will not be approved by the FDA - but dont despair, because we only need 1 or 2 of these to make it. The risks remain high (and why I allocate small amounts even to promising biotechs) but the potential for multibagger returns is very evident. Cheers! Matt Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 1 (ARRY) Terapixel (93.06) Submitted: 2/08/08 2:19 PM : Start Price: $5.59 ARRY Score: 41.52 They've got a legitimate six-drug pipeline - scooping up at 52-week low. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (ARRY) tomk0508 (92.93) Submitted: 2/04/08 12:22 AM : Start Price: $6.49 ARRY Score: 26.70 This is an interesting small cap company with a decent drug pipeline as well as some very intriguing technology for drug development. It is not clear that they have a winner in the pipeline yet but they do have one of the best drug development platforms available. Their platform allows development that is rapid and inexpensive and this should enable the company to excell over the longer term as they have solid scientific expertise in house. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (ARRY) PIcolano (81.95) Submitted: 12/21/07 3:38 PM : Start Price: $8.67 ARRY Score: 2.29 The depth of Array's pipeline is similar to Exelexis' pipeline, and should pay off handsomely for both companies over the long haul... Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 13 : 1 2 3 Next »

Wall Street

Results 1 - 12 of 12

picks per page. CHANGE Expand All Pitches Collapse All Pitches

Top Pick	Member Name	Member Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackWMBlair	34.40	02/07/08 02/07/08		NS	$5.66	+36.22%	-3.30%	+39.52
	TrackMorganJos	< 20	12/04/07 12/04/07		NS	$11.40	-32.37%	-12.58%	-19.79
	TrackCollinsStew	39.08	11/07/07 11/07/07		NS	$9.95	-22.51%	-14.78%	-7.74
	TrackLehmanBros	87.88	10/09/07 10/09/07		NS	$10.90	-29.27%	-17.60%	-11.66
	TrackEveillard	93.14	09/30/07 09/30/07		NS	$11.23	-31.34%	-15.97%	-15.37
	TrackRodmanRen	< 20	08/13/07 08/13/07		NS	$11.06	-30.29%	-12.48%	-17.80
	TrackJPMorgan	90.52	05/23/07 05/23/07		NS	$13.01	-40.74%	-16.18%	-24.56
	TrackPiperJaff	78.77	01/04/07 01/04/07		NS	$12.57	-38.66%	-9.22%	-29.44
	TrackOppenheimer	< 20	12/15/06 12/15/06		NS	$13.02	-40.78%	-10.24%	-30.54
	TrackWRHambrecht	42.19	11/09/06 11/09/06		NS	$11.92	-35.32%	-7.78%	-27.54
	TrackBofASec	96.35	11/02/06 11/02/06		NS	$9.60	-19.69%	-6.78%	-12.90
	TrackRWBaird	94.37	10/26/06 10/26/06		NS	$9.52	-19.01%	-7.57%	-11.45

Results 1 - 12 of 12

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.